AAP
ABBV icon

Aristotle Atlantic Partners’s AbbVie ABBV Stock Holding History

Aristotle Atlantic Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-3,000
Closed -$277K – 91
2018
Q4 		$277K Hold
3,000
– – 0.1% 79
2018
Q3 		$284K Buy
+3,000
New +$284K 0.17% 39

Other funds holding ABBV

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Aristotle Atlantic Partners's ABBV Position: Q1 2019 in Review

Aristotle Atlantic Partners sold out of AbbVie (ABBV) in Q1 2019, closing a stake of 3,000 shares — an estimated $277K sold.

Aristotle Atlantic Partners first reported a position in ABBV in Q3 2018 and held it in 2 quarters. The position peaked at $284K in Q3 2018. 2,033 funds tracked by Wall St. Rank hold ABBV as of Q1 2019.

  • Aristotle Atlantic Partners reported no remaining AbbVie position as of Q1 2019 after selling out during the quarter.
  • Aristotle Atlantic Partners sold 3,000 AbbVie shares in Q1 2019, an estimated $277K.
  • Aristotle Atlantic Partners first reported a position in AbbVie in Q3 2018 and held it in 2 quarters.
  • Aristotle Atlantic Partners's AbbVie position peaked at $284K in Q3 2018.
  • 2,033 funds tracked by Wall St. Rank held AbbVie as of Q1 2019.

Based on Aristotle Atlantic Partners's 13F filing for Q1 2019, filed 15 May 2019.